Endo’s move to trim manufacturing operations in the U.S. as part of a companywide restructuring plan has begun amid reports it has found a buyer for its Charlotte, NC, facility which the company had planned to close and let go of up to 300 employees.
The Dublin, Ireland-based company has found a buyer for the facility, which is operated by its Qualitest subsidiary, in-Pharma Technologist reported, citing an unnamed company spokeswoman. Details of the deal weren’t disclosed.
“We’ve actually entered into a formal agreement to sell the facility, signed earlier this week and, as part of the agreement, the new buyer has committed to retain 125 current employees,” the spokeswoman said.
Last week, Endo filed a WARN Act notice with the North Carolina Department of Commerce that said it planned to let go of 282 workers at the plant by the end of the year.
A similar WARN Act notice has yet to be filed in Alabama, where Endo previously said it will eliminate about 350 of the estimated 1,248 employees located at the plant.
The 88,000-square-foot Charlotte manufacturing operation produces tablets and capsules of generic drugs.
The layoffs and closure of the Charlotte plant are part of Endo’s response to revenue losses attributed to tighter competition in the generics market and delays on regulatory action for some of its products, the company said earlier this year.
With the restructuring, Endo hopes to save $60 million in 2017. The moves in the U.S. are mostly focused on Endo’s Qualitest operations, which the company acquired for $1.2 billion in 2010.
Editor’s Note: The story was updated to reflect a report that Endo had found an undisclosed buyer for the Charlotte, NC, plant.
By Joseph Keenan
Source: Fierce Pharma
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.